

Esophageal and Gastric Cancer Pearl: a nationwide clinical biobanking project in the Netherlands

L. Haverkamp,¹ K. Parry,¹ M. I. van Berge Henegouwen,² H. W. van Laarhoven,³ J. J. Bonenkamp,⁴ T. M. Bisseling,⁵ P. D. Siersema,⁶ M. N. Sosef,⁷ J. H. Stoot,⁸ G. L. Beets,⁹ W. O. de Steur,¹⁰ H. H. Hartgrink,¹⁰ H. W. Verspaget,¹¹ D. L. van der Peet,¹² J. T. Plukker,¹³ B. van Etten,¹³ B. P. L. Wijnhoven,¹⁴ J. J. van Lanschot,¹⁴ R. van Hillegersberg,¹ J. P. Ruurda¹

¹Departments of Surgery and ⁶Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht;

²Departments of Surgery and ³Medical Oncology, Academic Medical Center; ¹¹Parelsnoer Institute;

¹²Department of Surgery, VU Medical Center, Amsterdam; ⁴Departments of Surgery and ⁵Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen; ⁷Department of Surgery, Atrium Medical Center Parkstad, Heerlen; ⁸Department of Surgery, Orbis Medical Center, Sittard; ⁹Department of Surgery, Maastricht University Medical Center, Maastricht; ¹⁰Department of Surgery, Leiden University Medical Center, Leiden; ¹³Department of Surgery, University Medical Center Groningen, Groningen; and ¹⁴Department of Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands

SUMMARY. Esophageal and gastric cancer is associated with a poor prognosis since many patients develop recurrent disease. Treatment requires specific expertise and a structured multidisciplinary approach. In the Netherlands, this type of expertise is mainly found at the University Medical Centers (UMCs) and a few specialized nonacademic centers. Aim of this study is to implement a national infrastructure for research to gain more insight in the etiology and prognosis of esophageal and gastric cancer and to evaluate and improve the response on (neoadjuvant) treatment. Clinical data are collected in a prospective database, which is linked to the patients' biomaterial. The collection and storage of biomaterial is performed according to standard operating procedures in all participating UMCs as established within the Parelsnoer Institute. The collected biomaterial consists of tumor biopsies, blood samples, samples of malignant and healthy tissue of the resected specimen and biopsies of recurrence. The collected material is stored in the local biobanks and is encoded to respect the privacy of the donors. After approval of the study was obtained from the Institutional Review Board, the first patient was included in October 2014. The target aim is to include 300 patients annually. In conclusion, the eight UMCs of the Netherlands collaborated to establish a nationwide database of clinical information and biomaterial of patients with esophageal and gastric cancer. Due to the national coverage, a high number of patients are expected to be included. This will provide opportunity for future studies to gain more insight in the etiology, treatment and prognosis of esophageal and gastric cancer.

KEY WORDS: biobanking, esophageal and gastric cancer, the Netherlands.

Address correspondence to: Mr Jelle P. Ruurda, MD, PhD, University Medical Center Utrecht, Department of Surgery, PO BOX 85500, Utrecht, GA 3508, The Netherlands. Email: j.p.ruurda@umcutrecht.nl

The work described in this study was carried out in the context of the Parelsnoer Institute (PSI). PSI is part of and funded by the Dutch Federation of University Medical Centers and has received initial funding from the Dutch Government (from 2007–2011).

Author's contributions: LH participated in the design of the study and wrote the manuscript, KP wrote the manuscript, PS participated in the design of the study and revised the manuscript critically, HL participated in the design of the study and revised the manuscript critically, MBH participated in the design of the study and revised the manuscript critically, JB participated in the design of the study and revised the manuscript critically, TB participated in the design of the study and revised the manuscript critically, JP participated in the design of the study and revised the manuscript critically, BE participated in the design of the study and revised the manuscript critically, HH participated in the design of the study and revised the manuscript critically, WS participated in the design of the study and revised the manuscript critically, DP participated in the design of the study and revised the manuscript critically, MS participated in the design of the study and revised the manuscript critically, JS participated in the design of the study and revised the manuscript critically, JJ participated in the design of the study and revised the manuscript critically, BW participated in the design of the study and revised the manuscript critically, RH participated in the design of the study and revised the manuscript critically and JR participated in the design of the study and revised the manuscript critically. All authors read and approved the final manuscript.

INTRODUCTION

Esophageal and gastric cancer

The incidence of esophageal carcinoma is increasing in developed countries, whereas the incidence of gastric cancer has stabilized since its increase in the 1980s. The increase of esophageal cancer can mainly be attributed to the increase in adenocarcinoma of the esophagogastric junction among Caucasian males.¹⁻⁴ Esophageal cancer is now the sixth and gastric cancer the second leading cause of cancer-related mortality worldwide.^{3,4} The increased incidence of esophageal carcinoma was also reported in the Netherlands.⁵ In two decades (1989–2008), a threefold increase was seen for esophageal cancer, whereas the incidence of gastric cancer remained stable.⁵ The specific etiological factors that contributed to the dramatic increase and the prognosis of the disease are insufficiently elucidated.

Over the years, 5-year survival improved for esophageal cancer due to the increased use of neoadjuvant treatment and centralization of esophageal cancer surgery. However, 5-year survival remains poor.⁶⁻¹² The recently conducted CROSS trial showed that the overall 5-year survival after chemoradiotherapy combined with surgery was 47% in the Netherlands for patients with esophageal cancer.¹³ For cardia and non-cardia gastric cancer, long-term survival rates have not improved over the past 20 years.¹⁴ The reported survival rates were 33% and 50%, respectively, for cardia and non-cardia gastric cancer treated with surgery.¹⁴ Many patients with esophageal and gastric cancer develop metastatic disease or locoregional recurrence, and it remains difficult to predict which patients will develop recurrence disease.

Treatment of esophageal and gastric cancer requires a specific expertise and a structured multidisciplinary approach. This type of expertise is mainly found at the University Medical Centers (UMCs) and a few specialized nonacademic centers in our country. The UMCs have established a multidisciplinary collaboration to collect and store esophageal and gastric cancer biomaterial and to link this information to clinical data of the individual patients as part of the Parelinoer Institute (PSI).

History

The PSI was established in 2007 by the Dutch Federation of UMCs (NFU) with its main goal to ‘improve health by sharing science’. All eight UMCs of the Netherlands collaborated to achieve a nationwide database of clinical data and biomaterial for patients with selected medical conditions. Initially, eight different patients cohorts, the so-called ‘pearls’, were created by the PSI as seen in Table 1. However, over the years more patient cohorts followed, and the

Table 1 Parelinoer Institute

Year	Pearl (patient cohort)
2007	Cerebrovascular accident
	Type II diabetes mellitus
	Hereditary colorectal cancer
	Inflammatory bowel diseases (Crohn’s disease and ulcerative colitis)
	Leukemia
2010	Neurodegenerative diseases
	Rheumatoid arthritis
	Renal failure
2010	CONCOR (congenital heart disease)
2011	Multiple endocrine neoplasms
	Ischemic heart disease
	Pancreatic cancer and chronic pancreatitis
2014	Esophageal and gastric tumors
	Parkinson

Esophageal and Gastric Cancer Pearl is now the 14th patient cohort that has started collecting data. The overall aim of the PSI was to realize a national infrastructure within the UMCs to collect clinical data and to set up a national biobank to collect biomaterial. The clinical data are linked to the biomaterial, and therefore it can be used to conduct more advanced research. This may ultimately lead to better health care in patients with the selected medical condition, partly because treatment is more personalized (for further information: <http://www.parelinoer.org>).

Objective

The base of the Esophageal and Gastric Cancer Pearl is to implement a national infrastructure for research in patients with cancer of the esophagus and stomach. The scientific goal is to initiate and stimulate scientific research of high quality and of international importance. The main objective consists of three aims:

- To gain more knowledge in the etiology of esophageal and gastric cancer;
- To evaluate and improve the response on (neo)adjuvant and palliative treatment;
- To gain insight in the prognosis of esophageal and gastric cancer.

STUDY DESIGN

Inclusion criteria and informed consent

The protocols for this multicenter study were approved by the Institutional Review Board of the

Table 2 Work flow

	Time management							Executive
	T0	T1	T2	T3	T4	T5	T6–T10	
Informed consent	X	–	–	–	–	–	–	PhD candidate / nurse practitioner
Demographics	X	–	–	–	–	–	–	PhD candidate / nurse practitioner
Medical history	X	–	–	–	–	–	–	PhD candidate / nurse practitioner
Comorbidities	X	–	–	–	–	–	–	PhD candidate / nurse practitioner
Life style behavior	X	–	–	–	–	–	–	PhD candidate / nurse practitioner
Diagnosis-specific anamnesis	X	–	–	–	–	–	–	Specialist
Screening physical examination	X	–	–	–	–	–	–	Specialist
Collecting biopsies of suspected tumor	–	X	–	–	–	–	X	Endoscopist
Collecting blood samples	–	X	–	–	–	X	–	Specialist
Data neoadjuvant treatment	–	–	X	–	–	–	–	PhD candidate / nurse practitioner
Collecting tissue samples	–	–	–	X	–	–	–	Specialist
Surgical data	–	–	–	X	–	–	–	PhD candidate / nurse practitioner
Data postoperative	–	–	–	–	X	–	–	PhD candidate / nurse practitioner
Data adjuvant treatment	–	–	–	–	–	X	–	PhD candidate / nurse practitioner
Follow-up	–	–	–	–	–	–	X	PhD candidate / nurse practitioner

T0, date of inclusion; T1, day of upper gastrointestinal endoscopy; T2, after confirmation of diagnosis and before surgery; T3, day of surgery; T4, 30 days after surgery; T5, several weeks after surgery; T6, one year after surgery; T7, two years after surgery; T8, three years after surgery; T9, four years after surgery; T10, five years after surgery.

Biobank of the University Medical Center Utrecht. Patients with (suspected) esophageal or gastric tumors are eligible for inclusion into the esophageal and gastric cancer pearl if examination takes place in one of the following eight UMCs: Academic Medical Center Amsterdam, Free University Medical Center Amsterdam, University Medical Center Utrecht, Leiden University Medical Center, Erasmus Medical Center Rotterdam, University Medical Center Groningen, University Medical Center Nijmegen and Maastricht University Medical Center (Atrium Medical Center Heerlen, Orbis Medical Center Sittard). Patients who undergo either an upper gastrointestinal endoscopy with the taking of biopsies to confirm the diagnosis and/or who undergo an esophagectomy or gastrectomy are included into the Esophageal and Gastric Cancer Pearl. Informed consent must be fully understood and signed prior to the inclusion. The informed consent covers encoded clinical data, biobanking, permission to approach the municipality register for mortality follow-up and permission to contact the general practitioner of the patient to obtain important data. The participants receive a copy of the signed informed consent.

Data collection

Clinical data entry is performed by the local coordinating investigator. The prospective clinical database is kept separately from the biobank with a secure method to link encoded clinical information to tissue samples. This database can exclusively be accessed by authorized personnel. Biomaterial is also collected and stored locally by the coordinating investigator. Table 2 and Figure 1 shows the workflow and flow-chart of the study. The collected data contains the following items:

Demographics, patient’s characteristics and physical examination

During the first visit at the outpatient clinic of the participating hospital, information is gathered regarding the following items: gender, date of birth, family medical history, history of cancer-related illness or surgery, comorbidities, lifestyle behavior and drug use. Furthermore, a diagnosis-specific history is obtained (i.e. dysphagia, reflux disease, weight loss, etc.). Also, a screening physical examination is performed, including assessment of length and weight.

Diagnostic workup

All patients receive an upper gastrointestinal endoscopy. During endoscopy, biopsies of the suspected malignancy are taken to confirm the diagnosis of esophageal or gastric cancer and to retrieve biological characteristics of the tumor. If possible, an additional six biopsies are taken from the tumor to collect into the biobank. Immediately after excision, three of these samples are emersed in formalin in the endoscopy room. The other three biopsies are put in Eppendorf tubes with isopentane on dry ice to snap freeze at the endoscopy unit. At the department of pathology, the biopsies in formalin are embedded in paraffin and the biopsies in the Eppendorf tubes are directly put into the biobank freezers. Total time from endoscopic excision to fixation and snap freezing is kept to a minimum. Similarly, one paraffin biopsy and one snap freeze biopsy of normal mucosa are collected from the esophagus, the esophagogastric junction and from the stomach, if possible. The biopsies in paraffin are stored at room temperature and the snap-frozen biopsies at –80°C in the biobank.




Fig. 1 Flowchart of Esophageal and Gastric Cancer Pearl.

Blood samples

Samples of venous blood (serum, EDTA plasma and EDTA blood for deoxyribonucleic acid [DNA] extraction) are collected preoperatively and postoperatively. The blood samples are processed and stored in certified biobank laboratories of the UMCs. EDTA plasma and serum samples are obtained from 10 mL blood and are stored in 0.5 mL aliquots at -80°C in the biobank. EDTA blood samples for DNA extraction also consists of 10 mL blood, and after a quality control is performed the DNA, extracted within 4 weeks after venipuncture, is stored at 4°C or lower in the biobank. Maximum time for collecting, processing and storage of serum/plasma samples is 4 hours.

Treatment

If patients are eligible, they receive either neoadjuvant chemoradiation or perioperative chemotherapy depending on the site of the tumor and according to the Dutch upper gastrointestinal cancer guidelines.¹⁵ In case of a resectable tumor of the esophagus or stomach, patients undergo either an esophagus-cardia resection, partial or total gastrectomy or a total esophagogastrectomy. During surgery, the resection specimens are collected, and these are immediately transported in an unfixed state in a sterile closed box to the pathology department. At the department of pathology, the resection specimens are reviewed and if possible samples (0.5 cm^3) of the tumor are removed to collect into the biobank without compromising diagnostic histopathological staging. Three of these samples are embedded in paraffin, and three are immediately snap frozen in isopentane on dry ice in order to maintain a good quality of DNA/RNA. The pathologist also collects additional samples of normal tissue of

the esophagus, esophagogastric junction and stomach for storage in the biobank. Of each site, one sample is embedded in paraffin and one is snap frozen in isopentane. Total time from excision to snap freezing is estimated on 35 minutes. Information about the neoadjuvant treatment (chemotherapy or chemoradiotherapy) and the surgical procedure (type of resection, histopathological analysis) is entered in the prospective database.

Postoperative data and follow-up

Clinical data are collected until 30 days after surgery and consists of the following items: postoperative complications, mortality, readmission, radicality of resection, number of lymph nodes resected and stage according to the TNM staging system.¹⁶ In case a patient receives adjuvant treatment, information is entered in the database. Follow-up is maintained for a period of 5 years in the participating hospital. During these 5 years, data about local recurrences, distant metastasis, mortality and cause of death are collected annually. If biopsies of a suspected recurrence or metastasis are taken for histopathological confirmation, two additional biopsies are collected for storage in the biobank. One sample is embedded in paraffin, and one sample is snap frozen in isopentane.

Biobanking

All UMCs have their own storage for biomaterial, and together these storages form the national biobank for the Esophageal and Gastric Cancer Pearl. All materials are collected, identified, analyzed and stored in the biobank according to the standardized operating procedures established within the PSI to ensure homogenous sample

Table 3 Collecting biomaterial

Material	Amount	Frequency	Notification	Storage	Storage units
<i>Blood samples</i>					
1 EDTA plasma	1 × 10 mL	1 preoperative 1 postoperative	Mandatory Optional	−80°C	Preferably plasma 5 × 0.5 mL, optional blood/cell-pallet 3 × 0.9 mL
2 Serum	1 × 10 mL	1 preoperative 1 postoperative	Mandatory Optional	−80°C	Preferably 5 × 0.5 mL
3 EDTA blood sample for DNA or pellet from tube 1	1 × 10 mL	1 preoperative	Mandatory	4°C or ≤20°C	≥2 aliquots DNA stock solution
<i>Tissue samples</i>					
Biopsies tumor / and normal tissue (esophagus, EGJ, stomach)	12†	1 during endoscopy	Recommended	Three paraffin and three frozen samples from normal tissue one each	
Resection specimen	6 × 0.5 cm ³	1 at surgery	Mandatory	Preferably three paraffin and three frozen samples	
Normal tissue (esophagus, EGJ, stomach)	6 × 0.5 cm ³	1 at surgery	Mandatory	One paraffin and one frozen sample per site	
Biopsies recurrence/metastasis	2	Day of diagnostics	Recommended	One paraffin and one frozen sample	

†Only if possible. DNA, deoxyribonucleic acid; EDTA, Ethylenediaminetetraacetic acid; EGJ, esophagogastric junction.

collection. Each collected sample, as mentioned before and specified in Table 3, receives a unique sample code number, which is linked to the patient identification number through a biobank management information system software of the local biobank. Before clinical data linked to unique sample code numbers can be uploaded to the central database, the local patient's identification number is encrypted via a trusted third party by special software (Trusted Reversible Encryption Service®, Houten, Utrecht, The Netherlands) to respect the privacy of the donors and to ensure blinding of researchers to analysis. Hence, the central database contains encrypted clinical data linked to unique sample code numbers.

Research

All participating researchers can submit their study proposal to the scientific committee of the Esophageal and Gastric Cancer Pearl to conduct research with the clinical data and biomaterial gathered in the database. The scientific committee, consisting of two members of each UMC, judges the study proposal on the following criteria: the study will lead to novel insights regarding esophageal and gastric cancer, the study complies with requirements of an effective research methodology, the study will be performed by qualified investigators, the study is feasible and suitable. After acceptance of the research proposal by the scientific committee, the study can be conducted.

Funding

The founding of the PSI was co-financed by the Dutch Government, the NFU and the eight UMCs in the Netherlands. The continuation of the PSI is financed by the UMCs.

DISCUSSION

The biobank for the Esophageal and Gastric Cancer Pearl is designed to prospectively collect clinical data and biomaterial for research to gain more insight in its etiology, treatment and prognosis. In an era of increased interest in personalized medicine, the linkage of molecular data and genetic profiling to demographic, pathologic and clinical records will greatly enhance future studies of cancer etiology and risk factors. Moreover, the information about recurrences and survival status related to treatment therapies and genetic profiling will provide much information on progression and outcome of the disease.

Realizing their significance, biobanks have been established at national levels in many countries with strict regulations. For example, the General Practitioners Research Database in the UK was established to recruit more than half a million volunteers to collect blood and urine samples from 2006 to 2010.¹⁷ These samples were linked to information obtained from questionnaires and physical information and have been valuable in many research topics concerning diabetes, major depression, osteoporosis and

many more.^{18–20} Furthermore, the Esophageal and Gastric Center within the Academic Medical Center of Dublin has developed a repository of fresh frozen tissue, DNA, RNA and serum on patients with pre-malignant and malignant esophageal disease in 2004.²¹ They have collected samples of 420 patients in 6 years and used these samples for studies that included leptin and adiponectin receptor expression in esophageal cancer,²² prognostic significance of neuroepithelial transforming gene-1 in adenocarcinoma of the esophagogastric junction²³ and more. Lastly, the Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) study group in the UK has started a similar program for tissue and data collection of patients with esophageal cancer across multiple specialist centers. They aimed to determine prognostic biomarkers and therapeutic targets for esophageal adenocarcinoma including whole genome sequencing.^{24,25} Also in the Netherlands, a national biobank has been established (PSI), which originally started collecting data of eight patient cohorts. It has now grown to 14 patient cohorts of selected medical conditions, and its growth is still expanding.

The Esophageal and Gastric Cancer Pearl is established to implement a national infrastructure for research in patients with cancer of the esophagus and stomach, which will allow us to gain more insight in the etiology and prognosis of esophageal and gastric cancer and to evaluate and improve the response on (neoadjuvant) treatment. The specific strength of the Esophageal and Gastric Cancer Pearl is the ability to compare and follow patients with different stages of esophageal and gastric cancer at a molecular and genetic level, which brings us a step closer to the identification of biomarkers for the diagnosis and progression of the disease. Furthermore, it allows us to study the sensitivity and resistance to neoadjuvant treatment. Prediction of pathologically complete response and nonresponse to neoadjuvant chemoradiotherapy by analysis of tissues and genetic profiling is of great clinical importance and could allow to decide what is the optimal treatment in each individual. Another clear strength of the Esophageal and Gastric Cancer Pearl is that healthy tissue is collected from the esophagus, esophagogastric junction and stomach. This will allow to directly compare acquired disease-related alterations within the genetic background of the patients.

The most important factor for achieving our goals is the implementation of a solid national research infrastructure that contains a standardized data collection and a solid long-term storage strategy. Due to the longitudinal character of research with biobank materials, it is necessary to ensure data harmonization over a long period of time. This will contribute to high-quality investigations for generations of researchers. We are realizing this by the use of the

standard operating procedures to store biomaterial, which was released into the public domain by the Canadian Tumor Repository Network²⁶ and by a secured method to link clinical information to tissue samples. Some considerations are raised concerning ethics regarding the collection of data. Before inclusion of the patients in this study, written informed consent is required. Furthermore, data entry is uploaded in an encoded manner, in order to ensure privacy of the patients as well as remaining the possibility to trace biological samples and data back to the original participant for linkage to follow-up. However, only exclusive personnel are authorized to access the secured code.

PERSPECTIVES

Thanks to the collaboration between the UMCs, the Esophageal and Gastric Cancer Pearl has a national coverage. Most of the patients with esophageal and gastric cancer are treated in UMCs in our country and therefore a high percentage of these patients will be included into the Esophageal and Gastric Cancer Pearl. The first patient was included in October 2014, after which data collection has started. The target aim is to include 300 esophageal and gastric cancer patients annually. With this great number of patients, promising results can be expected in the near future.

CONCLUSION

In conclusion, the eight UMCs of the Netherlands collaborate within the Parelsnoer Institute to establish a nationwide database of clinical information and biomaterial in patients with esophageal and gastric cancer. This collection of data will aid in gaining more insight in the etiology and prognosis of esophageal and gastric cancer and to evaluate and improve the response on (neoadjuvant) treatment.

References

- 1 Devesa S S, Blot W J, Fraumeni J F Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. *Cancer* 1998; 83: 2049–53.
- 2 Bollschweiler E, Wolfgarten E, Gutschow C, Holscher A H. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. *Cancer* 2001; 92: 549–55.
- 3 Ferlay J, Shin H R, Bray F, Forman D, Mathers C, Parkin D M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2010; 127: 2893–917.
- 4 Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M J. Cancer statistics, 2009. *CA Cancer J Clin* 2009; 59: 225–49.
- 5 Dikken J L, Lemmens V E, Wouters M W *et al.* Increased incidence and survival for oesophageal cancer but not for gastric cardia cancer in the Netherlands. *Eur J Cancer* 2012; 48: 1624–32.
- 6 Solaymani-Dodaran M, Logan R F, West J, Card T, Coupland C. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. *Gut* 2004; 53: 1070–4.

- 7 Wouters M W, Karim-Kos H E, le Cessie S *et al.* Centralization of esophageal cancer surgery: does it improve clinical outcome? *Ann Surg Oncol* 2009; 16: 1789–98.
- 8 Rudiger Siewert J, Feith M, Werner M, Stein H J. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. *Ann Surg* 2000; 232: 353–61.
- 9 Mariette C, Castel B, Tournel H, Fabre S, Balon J M, Triboulet J P. Surgical management of and long-term survival after adenocarcinoma of the cardia. *Br J Surg* 2002; 89: 1156–63.
- 10 Ito H, Clancy T E, Osteen R T *et al.* Adenocarcinoma of the gastric cardia: what is the optimal surgical approach? *J Am Coll Surg* 2004; 199: 880–6.
- 11 Mattioli S, Di Simone M P, Ferruzzi L *et al.* Surgical therapy for adenocarcinoma of the cardia: modalities of recurrence and extension of resection. *Dis Esophagus* 2001; 14: 104–9.
- 12 Coupland V H, Lagergren J, Luchtenborg M *et al.* Hospital volume, proportion resected and mortality from oesophageal and gastric cancer: a population-based study in England, 2004–2008. *Gut* 2013; 62: 961–6.
- 13 van Hagen P, Hulshof M C, van Lanschot J J *et al.* Preoperative chemoradiotherapy for esophageal or junctional cancer. *N Engl J Med* 2012; 366: 2074–84.
- 14 Dassen A E, Dikken J L, van de Velde C J H, Wouters M W, Bosscha K, Lemmens V E. Changes in treatment patterns and their influence on long-term survival in patients with stages I–III gastric cancer in the Netherlands. *Int J Cancer* 2013; 133: 1859–66.
- 15 Integraal Kankercentrum Nederland, I. K. N. L. Oesofaguscarcinoom. Landelijke richtlijn, versie: 3.0. 2010.
- 16 Edge S B, Compton C C. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. *Ann Surg Oncol* 2010; 17: 1471–4.
- 17 Ollier W, Sprosen T, Peakman T. UK Biobank: from concept to reality. *Pharmacogenomics* 2005; 6: 639–46.
- 18 Harvey N C, Matthews P, Collins R, Cooper C, UK Biobank Musculoskeletal Advisory Group. Osteoporosis epidemiology in UK Biobank: a unique opportunity for international researchers. *Osteoporos Int* 2013; 24: 2903–5.
- 19 Smith D J, Nicholl B I, Cullen B *et al.* Prevalence and characteristics of probable major depression and bipolar disorder within UK biobank: cross-sectional study of 172,751 participants. *PLoS ONE* 2013; 8: e75362.
- 20 Tyrrell J S, Yaghootkar H, Freathy R M, Hattersley A T, Frayling T M. Parental diabetes and birthweight in 236 030 individuals in the UK Biobank Study. *Int J Epidemiol* 2013; 42: 1714–23.
- 21 Ennis D P, Pidgeon G P, Millar N, Ravi N, Reynolds J V. Building a bioresource for esophageal research: lessons from the early experience of an academic medical center. *Dis Esophagus* 2010; 23: 1–7.
- 22 Howard J M, Cathcart M C, Healy L *et al.* Leptin and adiponectin receptor expression in oesophageal cancer. *Br J Surg* 2014; 101: 643–52.
- 23 Lahiff C, Schilling C, Cathcart M C *et al.* Prognostic significance of neuroepithelial transforming gene 1 in adenocarcinoma of the oesophagogastric junction. *Br J Surg* 2014; 101: 55–62.
- 24 Peters C J, Rees J R, Hardwick R H *et al.* A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. *Gastroenterology* 2010; 139: 1995–2004.
- 25 Weaver J M, Ross-Innes C S, Shannon N *et al.* Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. *Nat Genet* 2014; 46: 837–43.
- 26 Canadian Tumour Repository Network, CTR. Standard Operating Procedures, 2004.